Wall Street Journal: The Coming Trials of Generation Zika
W. Ian Lipkin, professor of epidemiology and director of the Center for Infection and Immunity at Columbia University’s Mailman School of Public Health

“…The question is how large we will allow [Zika’s] impact to be. … The best path forward is a global vaccination program to reduce the impact of Zika here and in the developing world where resources to address the social and economic consequences are even more scarce. Unlike HIV, it will not be difficult to engineer an inexpensive and effective Zika vaccine. … It will take up to $1 billion and two to three years to complete the process of safety and efficacy testing, manufacture, and distribution. This is a nonpartisan challenge that cannot wait until after the November election. We must immediately invest the relatively modest resources needed to prevent our own and future generations from being defined by an infectious agent” (9/6).